HOPA Annual Conference - Hematology/Oncology Pharmacy Association Annual Conference

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

Factors (comorbidities, social factors) can largely affect the success of therapies in daily practice, despite findings observed in clinical trials.

And whatever specialty the student or resident decides on, it does not have to define the rest of their career.

Creating a safe environment for LGBTQ+ patients through the use of trauma informed care is critical to ensuring they feel comfortable returning to the clinic in the future.

There has been a historical lack of complete or appropriate data on sexual and gender minority groups, leading to difficulties in analyzing health outcomes in LGBTQ+ community.

Despite the potential for clinical benefit, triplet therapies have added complexities, monitoring needs, toxicities, and costs associated with additional pharmacologic therapy.

If patients with G6PD deficiency are exposed to risk factors, such as certain medications, environmental factors, or foods, it can lead to hemolysis.

Pharmacists have an important role in helping patients to identify treatment-related toxicities and manage symptoms to help the transition to the outpatient setting.

Some specialty pharmacy programs are even using electronic medical records to send survey tools to patients.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

The Hematology/Oncology Pharmacy Association (HOPA) created committees, inclusion statements, and diversity, equity, and inclusion (DEI) checkpoints to improve healthcare for underserved or historically less included populations.

Before tapering patients treated for cancer off of opioids, care providers should first establish what the goals of tapering are.

Certain populations have been found to have differing prognoses, such as African American patients, who have an earlier onset of disease with a higher likelihood of an aggressive tumor type and shorter survival.

Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.

Historically, there are many hard-to-treat mutations of non-small cell lung cancer.

President (2022 to 2023) of the Hematology Oncology Pharmacists Association (HOPA) highlights the many ways that hematology/oncology pharmacists can collaborate with care teams to improve access to care at HOPA Annual Conference 2023 in Phoenix, Arizona from March 29 to April 1.

Follow Pharmacy Times®’ live coverage of the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Phoenix, Arizona from March 29 to April 1, 2023.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses why a greater focus on colorectal cancer screening was important to highlight at the HOPA 2022 annual conference.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses key takeaways from the HOPA 2022 annual conference.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how experience as a caregiver can help inform the work of an oncology pharmacist on the clinical care team.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how oncology pharmacists with experience as a caregiver can utilize those skills while still honoring the boundaries of both themselves and their patients.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the unique struggles that come from being an oncology pharmacist and a caregiver.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how oncology pharmacists can help their patients overcome some of the barriers patients with cancer may encounter during treatment.

Benyam Muluneh, PharmD, BCOP, CPP, assistant professor at the University of North Carolina Eshelman School of Pharmacy, discusses his presentation at the HOPA 2022 annual conference on the Oral Chemotherapy Collaborative (OCC) and how it works to optimize care for patients taking oral anti-cancer agents.

Britny Brown, PharmD, BCOP, vice chair of the Hematology/Oncology Pharmacy Association (HOPA) DEI Task Force and clinical assistant professor at the University of Rhode Island College of Pharmacy, discusses the role of the task force within HOPA and its impact on the field more broadly.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers patients with cancer may experience that oncology pharmacists can help them navigate through.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers that patients with cancer may encounter following their diagnosis.

Session at the Hematology/Oncology Pharmacy Association Annual Conference 2022 focuses on methods to improve emotional exhaustion among pharmacists and other health care providers.

With risk stratification, up to 60% of individuals with chronic myeloid leukemia who are low-risk sustain treatment-free remission.

These include progression-free survival, time to treatment failure, and time to tumor progression, according to a presentation at the Hematology/Oncology Pharmacy Association conference.